Neprilysin
(Homo sapiens (Human)) | BDBM300285
(US9593110, 21-2)Show SMILES NC[C@H](C[C@@H](Cc1ccc(cc1)-c1cc(Cl)ccc1F)NC(=O)c1coc(n1)C1CC1)C(O)=O Show InChI InChI=1S/C25H25ClFN3O4/c26-18-7-8-21(27)20(11-18)15-3-1-14(2-4-15)9-19(10-17(12-28)25(32)33)29-23(31)22-13-34-24(30-22)16-5-6-16/h1-4,7-8,11,13,16-17,19H,5-6,9-10,12,28H2,(H,29,31)(H,32,33)/t17-,19+/m0/s1 | PDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 2.20 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Theravence Biopharma R&D IP, LLC
US Patent
| Assay Description Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp... |
US Patent US9593110 (2017)
BindingDB Entry DOI: 10.7270/Q2MC9224 |